OBJECTIVE: To study the effect of stable treatment with sodium oxybate (SO) on nocturnal REM sleep behavior disorder (RBD) and REM sleep without atonia (RSWA) that severely affected children with type 1 narcolepsy (NT1). METHODS: Nineteen children and adolescents with NT1 (9 female, mean age 12.5 ± 2.7 years, mean disease duration 3.4 ± 1.6 years) underwent neurologic investigations and video-polysomnography (v-PSG) at baseline and after 3 months of stable treatment with SO. v-PSG was independently analyzed by 2 sleep experts to rate RBD episodes. RSWA was automatically computed by means of the validated REM sleep atonia index (RAI). RESULTS: Compared to baseline, RAI significantly improved (p < 0.05) and complex movements during REM sleep were remarkably reduced after stable treatment with SO. Compared to baseline, children also reported improvement in clinical complaints and showed a different nighttime sleep-stage architecture. CONCLUSIONS: RBD and RSWA improved after treatment with SO, pointing to a direct role of the drug in modulating motor control during REM sleep. CLASSIFICATION OF EVIDENCE: This study offers Class IV evidence of the positive effect of SO on modulation of muscle atonia during REM sleep in children with NT1 because of the absence of a control group.
Antelmi E., Filardi M., Pizza F., Vandi S., Moresco M., Franceschini C., et al. (2021). REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate. NEUROLOGY, 96(2), e250-e254 [10.1212/WNL.0000000000011157].
REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
Filardi M.;Pizza F.;Vandi S.;
2021
Abstract
OBJECTIVE: To study the effect of stable treatment with sodium oxybate (SO) on nocturnal REM sleep behavior disorder (RBD) and REM sleep without atonia (RSWA) that severely affected children with type 1 narcolepsy (NT1). METHODS: Nineteen children and adolescents with NT1 (9 female, mean age 12.5 ± 2.7 years, mean disease duration 3.4 ± 1.6 years) underwent neurologic investigations and video-polysomnography (v-PSG) at baseline and after 3 months of stable treatment with SO. v-PSG was independently analyzed by 2 sleep experts to rate RBD episodes. RSWA was automatically computed by means of the validated REM sleep atonia index (RAI). RESULTS: Compared to baseline, RAI significantly improved (p < 0.05) and complex movements during REM sleep were remarkably reduced after stable treatment with SO. Compared to baseline, children also reported improvement in clinical complaints and showed a different nighttime sleep-stage architecture. CONCLUSIONS: RBD and RSWA improved after treatment with SO, pointing to a direct role of the drug in modulating motor control during REM sleep. CLASSIFICATION OF EVIDENCE: This study offers Class IV evidence of the positive effect of SO on modulation of muscle atonia during REM sleep in children with NT1 because of the absence of a control group.File | Dimensione | Formato | |
---|---|---|---|
e250.full.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
653.81 kB
Formato
Adobe PDF
|
653.81 kB | Adobe PDF | Visualizza/Apri |
File supplementari.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per accesso libero gratuito
Dimensione
13.28 MB
Formato
Zip File
|
13.28 MB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.